Evidence map›Paper›PMID 25288142›Full record

ArticleJAMA pediatrics2014

Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia.

Corinna L Schultz, Nandita Mitra, Marilyn M Schapira, Michele P Lambert

Abstract read
PubMed Publisher
In one paragraph

Article in JAMA pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pediatric ITP: is it different from adult ITP?Hematology. American Society of Hematology. Education Program · 2018
    Review
  5. Article
  6. Article
  7. Article
  8. [Classification therapy in 405 children with immune thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Corinna L SchultzChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania2currently with Alfred I. duPont Hospital for Children, Wilmington, Delaware.
Nandita MitraDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia4Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
Marilyn M SchapiraLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia5Perelman School of Medicine, University of Pennsylvania, Philadelphia6Center for Health Equity Research & Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsy.
Michele P LambertChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania5Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceIn 2011, the American Society of Hematology (ASH) published updated guidelines for the management of childhood immune thrombocytopenia (ITP) recommending management with observation alone when there are mild or no bleeding symptoms, regardless of platelet count. Little is known about practice patterns of newly diagnosed ITP in the United States.

objectiveTo understand the impact of management recommendations on practice patterns. DESIGN, SETTING, AND

participantsRetrospective medical record review in the Children's Hospital of Philadelphia, a large, urban, pediatric tertiary care hospital in Philadelphia, Pennsylvania. The study involved 311 pediatric patients with newly diagnosed ITP managed between January 1, 2007, and December 31, 2012. MAIN OUTCOMES AND MEASURES: Management type (observation alone vs pharmacotherapy) was determined via medical record review and electronic pharmacy data at diagnosis and within 6 months after diagnosis.

resultsOverall, 44.7% of patients were managed with observation alone at diagnosis, with a significant increase from 34.9% in 2007-2010 to 49.2% in 2011 (P < .02) and 71.1% in 2012 (P < .001). Of those treated, 99% were treated with intravenous immunoglobulin. In multivariable logistic regression, younger age (odds ratio, 0.92; 95% CI, 0.87-0.99), lower platelet count (odds ratio, 0.86; 95% CI, 0.83-0.89), and earlier period (2007-2010) of diagnosis (odds ratio, 0.17; 95% CI, 0.09-0.34) were significantly associated with increased odds of pharmacologic management. During 2010-2012, 20.8% of patients were also treated within 6 months after diagnosis. There was no significant difference by year or initial management type in those who received this later pharmacotherapy. Additionally, 19.6% of patients had documented bleeding symptoms beyond cutaneous bruising or petechiae at diagnosis. Intracranial hemorrhage at diagnosis was rare (0.6%). CONCLUSIONS AND RELEVANCE: We demonstrated a significant practice change in the management of newly diagnosed ITP at a pediatric care tertiary care hospital in the United States surrounding revision of the ASH management guidelines for childhood ITP. Our experience supports adoption of observation alone for a proportion of patients with newly diagnosed childhood ITP. This form of management did not lead to an increase in later treatment or an increase in delayed bleeding symptoms.

Indexed as

Practice Guidelines as TopicAdolescentAge FactorsChildChild, PreschoolHemorrhageHumansImmunoglobulins, IntravenousInfantMalePurpura, Thrombocytopenic, IdiopathicRetrospective StudiesTreatment OutcomeWatchful WaitingImmunoglobulins, Intravenous

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.